Erythropoietin-alfa During Neoadjuvant Chemotherapy for Locally Advanced Esophagogastric Adenocarcinoma

Abbrederis, K.; Bassermann, Florian; Schuhmacher, Christoph; Voelter, Verena; Busch, Raymonde; Roethling, N.; Sendler, A.; Siewert, J. R.; Peschel, Christian; Lordick, Florian

doi:10.1016/j.athoracsur.2006.01.097

Cited by 10 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, preoperative iron therapy is recommended for iron-deficiency anemia [17]. There is limited evidence in patients undergoing esophagectomy that erythropoietin (EPO; with or without iron) during neoadjuvant therapy increases hemoglobin and possible survival [73,74]. However, the lack of follow-up, lack of high-level evidence, and concerns regarding disease control indicate the need for further research and preclude recommendation.…”

Section: Potential Novel Pre-optimization Targetsmentioning

confidence: 99%

Nutrition in peri-operative esophageal cancer management

Steenhagen

Vulpen

Hillegersberg

et al. 2017

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Introduction: Nutritional status and dietary intake are increasingly recognized as essential areas in esophageal cancer management. Nutritional management of esophageal cancer is a continuously evolving field and comprises an interesting area for scientific research. Areas covered: This review encompasses the current literature on nutrition in the pre-operative, perioperative, and post-operative phases of esophageal cancer. Both established interventions and potential novel targets for nutritional management are discussed. Expert commentary: To ensure an optimal pre-operative status and to reduce peri-operative complications, it is key to assess nutritional status in all pre-operative esophageal cancer patients and to apply nutritional interventions accordingly. Since esophagectomy results in a permanent anatomical change, a special focus on nutritional strategies is needed in the post-operative phase, including early initiation of enteral feeding, nutritional interventions for post-operative complications, and attention to longterm nutritional intake and status. Nutritional aspects of pre-optimization and peri-operative management should be incorporated in novel Enhanced Recovery After Surgery programs for esophageal cancer.ARTICLE HISTORY

show abstract

Section: Potential Novel Pre-optimization Targetsmentioning

confidence: 99%

Nutrition in peri-operative esophageal cancer management

Steenhagen

Vulpen

Hillegersberg

et al. 2017

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

show abstract

“…12,13 Although H pylori gastritis contributes to the risk of noncardia adenocarcinoma, it may be protective for proximal adenocarcinoma. 14,15 Furthermore, gene-environmental interaction [16][17][18] may influence susceptibility to the consequences of H pylori gastritis.…”

mentioning

confidence: 99%

Gastric Cancer—An Enigmatic and Heterogeneous Disease

Shah

Ajani²

2010

JAMA

100

View full text Add to dashboard Cite

“…Moreover, treatment with EB was able to elude preoperative anemia in patients with levels of Hb B 11 g/dl without greatly interfering in the rate of surgical complications usually encountered in this setting, either in alpha-epoetin-treated patients (16%) [25] or regardless of hematopoietic correction (27.7-31.2%) [26,27].…”

Section: Resultsmentioning

confidence: 99%

Anemia response and safety to epoetin-beta treatment in patients with neoadjuvant therapy prior to primary digestive tract tumor surgery

Gómez

Salgado

Valladares‐Ayerbes

et al. 2009

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Purpose Anemia is common during anticancer treatment. This study aimed to evaluate the response and safety of treatment with epoetin-beta (EB) in patients with neoadjuvant therapy prior to primary digestive tract tumor surgery. Patients and methodsIn this open-label, single-arm study, patients (n = 22) with hemoglobin (Hb) levels below 11 g/dl who received epoetin-beta 450 IU/kg (30,000 IU) weekly until the hemoglobin level reached 12 g/dl.Results After treatment with EB, a mean absolute increment of 2.6 g/dl was attained. The mean hemoglobin values during the study were pretreatment 10.1 g/dl, half-way through treatment 12.3 g/dl, 4 weeks after concomitant radiochemotherapy 12.7 g/dl, the week prior to surgery 12.5 g/dl, and after surgery 10.9 g/dl. No patient required transfusion before or after surgery. The probability or risk of postoperative complications was 27.3%, and included one rectovaginal fistula, one parastomal hernia, one case of ileus and two surgical wound infections. In this series, downstaging was observed in 81.8% of patients, and downsizing in 90.9%. Most interestingly, histopathological complete response rate was achieved by 18.2%. Conclusions Epoetin-beta (EB) treatment in our series of patients with digestive malignancies subjected to neoadjuvant radiochemotherapy proved effective and safe, avoiding the need for transfusion during surgery.

show abstract

Erythropoietin-alfa During Neoadjuvant Chemotherapy for Locally Advanced Esophagogastric Adenocarcinoma

Cited by 10 publications

References 31 publications

Nutrition in peri-operative esophageal cancer management

Nutrition in peri-operative esophageal cancer management

Gastric Cancer—An Enigmatic and Heterogeneous Disease

Anemia response and safety to epoetin-beta treatment in patients with neoadjuvant therapy prior to primary digestive tract tumor surgery

Contact Info

Product

Resources

About